The fourth-quarter results represent the culmination of a challenging fiscal year for Heranba Industries, with the company posting a full-year net profit of just ₹2.00 crores for FY25 on revenues of ₹1,409.00 crores—a dramatic collapse from the ₹34.00 crore profit achieved in FY24. The micro-cap company, which specialises in synthetic pyrethroids and agrochemical intermediates, now faces mounting investor scepticism as operational losses persist despite modest revenue growth.
The market's harsh verdict is evident in the stock's trajectory: down 40.34% over the past year and a staggering 75.23% over five years, significantly underperforming both the Sensex and its sector peers. With the stock trading at 0.93 times book value and institutional holdings at a meagre 0.35%, Heranba Industries confronts critical questions about its operational viability and strategic direction.
| Quarter | Revenue (₹ Cr) | QoQ Growth | Net Profit (₹ Cr) | QoQ Growth | Operating Margin |
|---|---|---|---|---|---|
| Mar'26 | 319.48 | +6.01% | -57.82 | +148.69% | -7.28% |
| Dec'25 | 301.37 | -42.23% | -23.25 | +1503.45% | 4.12% |
| Sep'25 | 521.71 | +15.31% | -1.45 | -123.77% | 9.36% |
| Jun'25 | 452.43 | +35.15% | 6.10 | -114.70% | 6.90% |
| Mar'25 | 334.77 | -1.91% | -41.49 | +307.16% | -4.33% |
| Dec'24 | 341.29 | -21.98% | -10.19 | -126.84% | 3.67% |
| Sep'24 | 437.42 | — | 37.97 | — | 13.61% |
Financial Performance: A Deteriorating Trajectory
Heranba Industries' Q4 FY26 results reveal a company in deep operational distress. Net sales in the March quarter stood at ₹319.48 crores, registering a modest 6.01% sequential increase from ₹301.37 crores in Q3 FY26, but declining 4.57% year-on-year from ₹334.77 crores in Q4 FY25. This revenue contraction, whilst seemingly marginal, masks a more severe underlying problem: the company's inability to convert top-line growth into profitability.
The operating profit before depreciation, interest, tax, and other income (PBDIT excluding OI) collapsed to a negative ₹23.26 crores in Q4 FY26, representing a dismal operating margin of -7.28%—the lowest recorded in at least eight quarters. This compares unfavourably with the 4.12% margin achieved in the previous quarter and marks a dramatic reversal from the 13.61% margin reported in September 2024. The erosion of operating profitability signals fundamental issues with cost management, pricing power, or both.
Interest costs remained elevated at ₹13.77 crores in Q4 FY26, reflecting the company's heightened debt burden following significant capital expenditure. With depreciation charges at ₹25.47 crores—substantially higher than the ₹15.58 crores recorded in Q4 FY25—the company's fixed cost structure has become increasingly onerous. The combination of negative operating profits, elevated interest, and rising depreciation resulted in a pre-tax loss of ₹68.01 crores for the quarter.
On a full-year basis, FY25 proved equally challenging. Despite achieving 12.10% revenue growth to ₹1,409.00 crores, the company's net profit collapsed to just ₹2.00 crores from ₹34.00 crores in FY24—a staggering 94.12% decline. The PAT margin compressed to a mere 0.10%, down from 2.70% in the previous year, whilst operating margins contracted from 6.00% to 6.90%, offering little solace given the substantial increase in depreciation and interest costs.
Operational Distress: The Capital Efficiency Crisis
The company's return on equity (ROE) has turned sharply negative at -5.59%, signalling active capital destruction for shareholders. This represents a precipitous fall from the already weak average ROE of 4.37% over recent years. With shareholders' funds of ₹840.80 crores as of March 2025, the company is effectively eroding the capital base entrusted to it by investors—a red flag that cannot be ignored.
Return on capital employed (ROCE) paints an equally bleak picture, standing at a meagre 0.12% as of the latest quarter, down from an already anaemic average of 7.85%. For a capital-intensive manufacturing business, such low returns indicate severe operational inefficiencies and question the wisdom of the substantial capacity expansion undertaken in recent years.
⚠️ Critical Alert: Capital Destruction in Progress
Heranba Industries' negative ROE of -5.59% and near-zero ROCE of 0.12% represent active destruction of shareholder capital. The company's ambitious capacity expansion has resulted in fixed assets ballooning to ₹662.34 crores (from ₹445.12 crores in FY24), but these investments are generating negative returns. With interest costs rising 150% year-on-year and operating losses mounting, the company faces a critical juncture where operational turnaround is imperative to avoid further value erosion.
The balance sheet reveals the strain of aggressive expansion. Long-term debt surged to ₹92.69 crores in FY25 from just ₹17.91 crores in FY24, whilst current liabilities jumped to ₹859.58 crores from ₹599.03 crores, driven primarily by a massive increase in trade payables to ₹486.40 crores. This suggests potential working capital stress and possible delays in supplier payments—a concerning development for a company already grappling with profitability challenges.
The Agrochemical Headwinds: Industry Context
Heranba Industries operates in the highly competitive pesticides and agrochemicals sector, where pricing pressure, raw material volatility, and intense competition from Chinese manufacturers have created a challenging operating environment. The sector has witnessed margin compression across the board, with inventory destocking cycles impacting demand patterns globally.
The company's focus on synthetic pyrethroids and intermediates exposes it to both feedstock price volatility and end-market demand fluctuations. With agrochemical prices softening globally and Chinese competition intensifying post-pandemic supply chain normalisation, Indian manufacturers have faced sustained pressure on realisations. Heranba's negative operating margins suggest it has been particularly vulnerable to these headwinds, possibly due to unfavourable long-term contracts or inability to pass on cost increases.
The sector's one-year return of -12.91% reflects these broader challenges, but Heranba's 40.34% decline significantly underperforms this benchmark, indicating company-specific issues beyond sectoral headwinds. This underperformance suggests execution challenges, market share losses, or structural cost disadvantages that peers have better managed.
| Company | P/E Ratio | P/BV Ratio | ROE (%) | Debt/Equity | Div Yield (%) |
|---|---|---|---|---|---|
| Heranba Industries | NA (Loss Making) | 0.93 | 4.37 | 0.56 | 0.51 |
| India Pesticides | 16.10 | 1.91 | 14.34 | -0.01 | 0.45 |
| Astec Lifesciences | NA (Loss Making) | 4.30 | 5.75 | 1.12 | — |
| Meghmani Organics | 44.42 | 0.83 | 7.13 | 0.45 | — |
| Punjab Chemicals | 18.74 | 2.90 | 20.38 | 0.33 | 0.30 |
| Dharmaj Crop | 17.61 | 2.44 | 11.64 | 0.28 | — |
Peer Comparison: Lagging on All Metrics
When benchmarked against sectoral peers, Heranba Industries' underperformance becomes starkly apparent. The company's ROE of 4.37% trails significantly behind India Pesticides (14.34%), Punjab Chemicals (20.38%), and Dharmaj Crop (11.64%). Even amongst loss-making peers like Astec Lifesciences, Heranba's capital efficiency metrics lag.
The company's price-to-book ratio of 0.93 times—below its book value—reflects the market's deep scepticism about management's ability to generate adequate returns on invested capital. Whilst this might appear to offer a margin of safety, the negative ROE suggests the book value itself is overstated relative to the company's earning power. In contrast, profitable peers command P/BV multiples ranging from 1.91x to 4.30x, reflecting investor confidence in their operational capabilities.
Heranba's debt-to-equity ratio of 0.56, whilst moderate in absolute terms, becomes concerning when viewed alongside negative profitability. Peers like India Pesticides operate with negligible debt, whilst Punjab Chemicals and Dharmaj Crop maintain lower leverage ratios of 0.33 and 0.28 respectively. The company's dividend yield of 0.51%, maintained despite losses, raises questions about sustainability—indeed, the dividend payout ratio of 130.33% indicates the company is paying out more than it earns, an unsustainable practice that further strains the balance sheet.
Valuation Analysis: Expensive Despite Losses
Paradoxically, despite loss-making operations, Heranba Industries trades at what can only be described as "expensive" levels relative to its fundamentals. The company's EV/EBITDA multiple of 16.11x appears elevated given the deteriorating earnings trajectory, whilst the EV/Sales ratio of 0.78x suggests the market is pricing in significant operational improvement that has yet to materialise.
The stock's classification as "EXPENSIVE" in valuation grade assessments reflects this disconnect between market pricing and underlying fundamentals. With the stock having declined 55.30% from its 52-week high of ₹403.40, one might expect valuation metrics to appear attractive. However, the rapid deterioration in profitability has eroded any valuation cushion, leaving the stock vulnerable to further downside should operational challenges persist.
Valuation Dashboard
The company's market capitalisation of ₹721.44 crores positions it firmly in micro-cap territory, adding liquidity risk to an already challenging investment proposition. With institutional holdings at just 0.35% and mutual fund participation virtually absent (0.00%), the stock lacks the support of sophisticated investors who typically provide stability during volatile periods.
Shareholding Pattern: Promoter Stability Amid Institutional Exodus
One of the few positive aspects of Heranba Industries' investment profile is the stable promoter holding of 74.94%, which has remained unchanged over the past five quarters. This unwavering commitment from the founding Shetty family, led by Raghuram Kanyan Shetty (29.77%) and Sadashiv Kanyana Shetty (18.00%), provides some reassurance that insiders remain aligned with long-term shareholder interests. Importantly, there is zero promoter pledging—a critical positive in an otherwise challenging narrative.
| Quarter | Promoter | FII | MF | Insurance | Other DII | Public |
|---|---|---|---|---|---|---|
| Mar'26 | 74.94% | 0.07% | 0.00% | 0.00% | 0.27% | 24.71% |
| Dec'25 | 74.94% | 0.08% | 0.00% | 0.00% | 0.27% | 24.70% |
| Sep'25 | 74.94% | 0.05% | 0.00% | 0.00% | 0.27% | 24.73% |
| Jun'25 | 74.94% | 0.05% | 0.00% | 0.00% | 0.27% | 24.73% |
| Mar'25 | 74.94% | 0.10% | 0.00% | 0.00% | 0.21% | 24.75% |
However, the near-complete absence of institutional investors tells a sobering story. FII holdings have dwindled to just 0.07% (down from 0.10% in March 2025), mutual funds hold no stake whatsoever, and insurance companies have no exposure. This institutional void reflects sophisticated investors' assessment of the company's risk-reward profile as unattractive. The modest Other DII holding of 0.27% provides little comfort, representing just four FII entities with marginal positions.
Stock Performance: A Relentless Decline
The stock's price performance has been nothing short of catastrophic across all timeframes. Trading at ₹180.30 as of May 29, 2026, Heranba Industries has declined 40.34% over the past year, massively underperforming the Sensex's -6.94% return by a painful 33.40 percentage points of negative alpha. The stock trades below all key moving averages—5-day (₹190.89), 20-day (₹206.63), 50-day (₹196.86), 100-day (₹206.81), and 200-day (₹252.80)—signalling entrenched bearish sentiment.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Day | -7.59% | +0.14% | -7.73% |
| 1 Week | -4.98% | +0.74% | -5.72% |
| 1 Month | -18.93% | -1.97% | -16.96% |
| 3 Months | -13.40% | -6.54% | -6.86% |
| 6 Months | -29.61% | -11.36% | -18.25% |
| YTD | -26.90% | -10.85% | -16.05% |
| 1 Year | -40.34% | -6.94% | -33.40% |
| 2 Years | -40.13% | +1.97% | -42.10% |
| 3 Years | -47.19% | +20.88% | -68.07% |
| 5 Years | -75.23% | +47.74% | -122.97% |
The longer-term picture is even more distressing. Over three years, the stock has lost 47.19% whilst the Sensex gained 20.88%—a staggering 68.07 percentage points of underperformance. The five-year return of -75.23% versus the Sensex's +47.74% represents a wealth destruction of epic proportions for long-term holders. With a beta of 1.17, the stock exhibits higher volatility than the market, amplifying losses during downturns without commensurate gains during recoveries.
Technical indicators uniformly point to continued weakness. The MACD shows bearish signals on monthly timeframes, Bollinger Bands indicate mildly bearish to bearish trends, and the overall technical classification remains "MILDLY BEARISH." The stock's immediate support lies at the 52-week low of ₹155.80—just 13.59% below current levels—whilst meaningful resistance sits at the 200-day moving average of ₹252.80, implying a 40.21% rally would be required to reclaim that level.
Investment Thesis: A Turnaround Nowhere in Sight
The proprietary Mojo Score of 28 out of 100 places Heranba Industries firmly in "STRONG SELL" territory—a rating that appears entirely justified given the confluence of negative factors. The company scores poorly across all four key parameters assessed by the Mojo framework:
Mojo 4 Dots Analysis
1. Near Term Drivers: NEGATIVE
Both quarterly financial trend (classified as "Negative") and technical indicators (Mildly Bearish) point to continued weakness in the immediate term.
2. Quality: BELOW AVERAGE
Weak ROE (4.37%), declining EBIT growth (-141.01% over 5 years), and elevated debt relative to EBITDA (2.36x) signal structural quality issues.
3. Valuation: RISKY
Despite trading below book value, the company's loss-making status and deteriorating fundamentals make current valuations risky rather than attractive.
4. Overall Assessment: CAUTIOUS
Mixed signals across parameters, but with a distinct negative bias given operational losses and capital destruction.
The financial trend analysis reveals eight consecutive quarters of deteriorating metrics, with the March 2026 quarter marking new lows in operating profitability, interest coverage, and earnings per share. The company's interest coverage ratio has collapsed to -1.69 times, indicating it cannot even service its debt obligations from operating profits—a precarious position that raises going concern questions if not addressed swiftly.
Key Strengths & Risk Factors
✓ Key Strengths
- Stable Promoter Base: 74.94% holding by founding family with zero pledging demonstrates long-term commitment
- Established Market Presence: Three decades of operations in agrochemicals with technical expertise in synthetic pyrethroids
- Long-term Revenue Growth: 5-year sales CAGR of 13.08% shows demand for products despite recent challenges
- Expanded Capacity: Recent capex has significantly increased production capacity, providing potential for scale benefits
- Dividend Track Record: Maintained dividend payments despite losses, signalling confidence in eventual turnaround
⚠ Key Concerns
- Persistent Losses: Three consecutive quarters of losses with Q4 FY26 marking the worst performance in years
- Negative ROE: -5.59% ROE indicates active capital destruction and raises questions about management effectiveness
- Margin Collapse: Operating margin of -7.28% in Q4 FY26 reflects severe pricing pressure or cost management failures
- Rising Debt Burden: Long-term debt surged 417% to ₹92.69 crores whilst profitability evaporated
- Working Capital Stress: Trade payables jumped 68% to ₹486.40 crores, suggesting potential payment delays
- Institutional Abandonment: Near-zero institutional holdings (0.35%) reflects lack of confidence from sophisticated investors
- Consistent Underperformance: 75.23% decline over five years versus Sensex gain of 47.74%
Outlook: What Lies Ahead
Positive Catalysts to Monitor
- Return to positive operating margins through pricing improvement or cost rationalisation
- Capacity utilisation improvement as new facilities stabilise and reach optimal output
- Recovery in agrochemical demand globally as destocking cycles complete
- Successful negotiation of better pricing terms with customers as contracts come up for renewal
- Strategic cost reduction initiatives bearing fruit in coming quarters
Red Flags to Watch
- Further deterioration in operating margins below -7% levels
- Continued negative cash flow from operations straining liquidity
- Inability to service debt obligations leading to covenant breaches
- Additional capacity expansion announcements without clear path to profitability
- Promoter stake dilution or pledging of shares to meet working capital needs
- Loss of market share to more efficient domestic or Chinese competitors
The path forward for Heranba Industries requires urgent operational remediation. Management must prioritise returning to positive operating profitability through aggressive cost reduction, pricing discipline, and capacity rationalisation. The company's survival depends on stemming cash burn, stabilising working capital, and demonstrating to investors that recent capacity investments can generate adequate returns. Until these fundamentals improve materially, the stock remains uninvestable at any price.
The Verdict: Exit Recommended
Score: 28/100
For Fresh Investors: Avoid entirely. Heranba Industries exhibits all the hallmarks of a deteriorating business—mounting losses, negative ROE, collapsing margins, and rising debt. The company's operational challenges show no signs of abating, and the risk of further value destruction remains elevated. Better opportunities exist elsewhere in the agrochemical space with profitable, well-managed companies trading at reasonable valuations.
For Existing Holders: Strongly consider exiting positions at current levels, accepting the loss as a prudent risk management decision. The stock's 75% decline over five years demonstrates the danger of holding onto deteriorating businesses hoping for a turnaround. With negative cash flow from operations, rising debt, and persistent losses, the risk of further downside significantly outweighs any potential recovery. The company needs to demonstrate at least two consecutive quarters of positive operating profits before reconsidering investment merit.
Fair Value Estimate: ₹145-155 (19.40% downside from current levels), reflecting the elevated risk of continued operational losses and potential balance sheet stress. Even at these levels, investment remains speculative until operational turnaround is demonstrated.
Note— ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results, and all investments carry risk of loss.
